DESCOVY 200 mg/25 mg, tablet film-coated 30 tablets
Active ingredients: Emtricitabine, Tenofovir alafenamide fumarate, Tenofovir alafenamide
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DESCOVY 200 mg/25 mg, comprime pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
- Marketing authorisation holder
- GILEAD SCIENCES IRELAND UC (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Sept 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66325208CIP73005734CIP133400930057346Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| EMTRICITABINEcomprimé | 200 mg · un comprimé | SA |
| FUMARATE DE TÉNOFOVIR ALAFÉNAMIDEcomprimé | — | SA |
| TÉNOFOVIR ALAFÉNAMIDEcomprimé | 25 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.